ArticleAntibiotics (Basel, Switzerland)2021
The Spread of NDM-1 and NDM-7-Producing
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Genomic inference of sites of transmission during regional spread of blaNature communications · 2026Article
- In Vitro Evaluation of Fosfomycin Combinations Against Metallo-β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Clinical carbapenem-resistantMicrobiology spectrum · 2025Article
- Nationwide Burden of Metallo-β-Lactamase Genes in Brazilian ClinicalAntibiotics (Basel, Switzerland) · 2025Review
- Impact of the COVID-19 Pandemic on Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Double-carbapenemase-producing Enterobacteriaceae: complete genome sequencing of isolates from hospitals in Paraguay, 2021.Revista peruana de medicina experimental y salud publica · 2025Article
- Clonal overlap and resistance profiles of multidrug-resistantVeterinary world · 2025Article
- Genomic characterization of plasmids harboringMicrobiology spectrum · 2025Article
- Emergence of NDM-7-ProducingMicroorganisms · 2025Article
- Polyclonal carbapenemase-producingFrontiers in cellular and infection microbiology · 2025Article
- Review
- Genomic Characterization of NDM-1 Harboring Extensively-Drug ResistanceJournal of tropical medicine · 2025Article
- Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Genomics ofMicroorganisms · 2022Article
- Occurrence of blaArchives of microbiology · 2022Article
- A case-control study of infections caused byFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Carbapenem resistance among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.